Ten63 Therapeutics

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Ten63 Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $763.2M in funding across 48 round(s). With a team of 11-50 employees, Ten63 Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Ten63 Therapeutics, raised $15.9M. Discover more about their projects, partnerships, and impact on our platform.